ProMIS Neurosciences (DB:23J0) - Stock Price, News & Analysis

23J0 Stock Overview

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. More details

23J0 fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Risk Analysis

Makes less than USD$1m in revenue ($0)

Earnings have declined by 18.1% per year over past 5 years

Has less than 1 year of cash runway

Highly volatile share price over the past 3 months compared to the German market

+ 2 more risks

ProMIS Neurosciences, Inc. Competitors

Medigene

XTRA:MDG1

€22.6m

4SC

DB:VSC

€48.2m

co.don

XTRA:CNW

€6.5m

2invest

XTRA:2INV

€63.8m

Price History & Performance

Summary of all time highs, changes and price drops for ProMIS Neurosciences
Historical stock prices
Current Share Price	US$0.89
52 Week High	US$2.44
52 Week Low	US$0.76
Beta	0.61
11 Month Change	16.34%
3 Month Change	-11.88%
1 Year Change	-25.83%
33 Year Change	-85.17%
5 Year Change	-88.32%
Change since IPO	-85.46%

Recent updates

Shareholder Returns

	23J0	DE Biotechs	DE Market
7D	-2.2%	-0.7%	0.2%
1Y	-25.8%	-17.2%	8.5%

Return vs Industry: 23J0 underperformed the German Biotechs industry which returned -17.2% over the past year.

Return vs Market: 23J0 underperformed the German Market which returned 8.5% over the past year.

Price Volatility

Is 23J0's price volatile compared to industry and market?
23J0 volatility
23J0 Average Weekly Movement	17.7%
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.3%

Stable Share Price: 23J0's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 23J0's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
2004	7	Neil K. Warma	www.promisneurosciences.com

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils.

ProMIS Neurosciences, Inc. Fundamentals Summary

How do ProMIS Neurosciences's earnings and revenue compare to its market cap?
23J0 fundamental statistics
Market cap	€19.90m
Earnings (TTM)	-€540.98k
Revenue (TTM)	n/a

0.0x

P/S Ratio

-36.8x

P/E Ratio

Is 23J0 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
23J0 income statement (TTM)
Revenue	US$0
Cost of Revenue	US$2.23m
Gross Profit	-US$2.23m
Other Expenses	-US$1.66m
Earnings	-US$563.35k

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.028
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did 23J0 perform over the long term?

See historical performance and comparison

23J0 Stock Overview

Risk Analysis

ProMIS Neurosciences, Inc. Competitors

XTRA:MDG1

€22.6m

DB:VSC

€48.2m

XTRA:CNW

€6.5m

XTRA:2INV

€63.8m

Price History & Performance

Recent News & Updates

ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology

ProMIS Neurosciences, Inc. Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer's Association International Conference

ProMIS Neurosciences, Inc. announced that it expects to receive CAD 30.3 million in funding from Great Point Partners, LLC, Armistice Capital LLC, Ally Bridge Group, Sphera Funds Management Ltd and other investors

ProMIS Neurosciences, Inc. Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial

ProMIS Neurosciences Receives Written Notice from Nasdaq Due to Non-Compliance with Nasdaq Listing Rule 5550(b)(2)

ProMIS Neurosciences, Inc. Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies

Recent updates

ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology

ProMIS Neurosciences, Inc. Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer's Association International Conference

ProMIS Neurosciences, Inc. announced that it expects to receive CAD 30.3 million in funding from Great Point Partners, LLC, Armistice Capital LLC, Ally Bridge Group, Sphera Funds Management Ltd and other investors

ProMIS Neurosciences, Inc. Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial

ProMIS Neurosciences Receives Written Notice from Nasdaq Due to Non-Compliance with Nasdaq Listing Rule 5550(b)(2)

ProMIS Neurosciences, Inc. Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies

ProMIS Neurosciences Inc. Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as A Treatment Target for ALS

ProMIS Neurosciences, Inc., Annual General Meeting, Jun 13, 2024

ProMIS Neurosciences, Inc. has filed a Follow-on Equity Offering in the amount of $25 million.

ProMIS Neurosciences, Inc. has filed a Follow-on Equity Offering in the amount of $25 million.

ProMIS Neurosciences Announces Publication on Novel Target for ALS

Promis Neurosciences Inc. Doses First Subjects in Phase 1A Clinical Trial of PMN310 to Treat Alzheimer's Disease

ProMIS Neurosciences to Delist from TSX

ProMIS Neurosciences Inc. Announces FDA Clearance of Investigational New Drug Application for PMN310 in Alzheimer’s Disease

No longer forecast to breakeven

ProMIS Neurosciences, Inc. announced that it has received $7.472277 million in funding from Kraft Group LLC and other investors

ProMIS Neurosciences Appoints Gail M. Farfel as Chief Executive Officer

ProMIS Neurosciences, Inc. to Present At 2022 Alzheimer's Association International Conference

ProMIS Neurosciences Common Shares Deleted from Other OTC

ProMIS Neurosciences, Inc. Appoints Larry Altstiel as Chief Medical Officer

ProMIS Neurosciences, Inc. Announces Pmn310 Antibody Demonstrates Significant Cognitive Benefit in A Mouse Model of Alzheimer’s Disease

ProMIS Neurosciences, Inc. Announces Board Appointments

ProMIS Neurosciences Appoints Cheryl Wellington to its Scientific Advisory Board

ProMIS Neurosciences, Inc. Initiates Program to Develop Monoclonal Antibodies to Treat Schizophrenia and Other Chronic Mental Illnesses

ProMIS Neurosciences, Inc. has completed a Composite Units Offering in the amount of $17.5 million.

ProMIS Neurosciences, Inc. Initiates Commercialization of Covid-19 Serology Assay

ProMIS Neurosciences Re-Initiates Path to IND for PMM310 with Producer Cell Line Development

ProMIS Neurosciences, Inc. announced that it has received CAD 8.75 million in funding from Kraft Group LLC and other investors

ProMIS Neurosciences, Inc. Announces Perspectives on Recent Progress in the Alzheimer's Field

Revenue in line with expectations

ProMIS Neurosciences Adds Dr. David Wishart to Its Scientific Advisory Board

ProMIS Neurosciences, Inc. Presents Lead Program for Alzheimer's Disease at Prestigious Keystone Symposia Scientific Conference

ProMIS Neurosciences, Inc. Announces Resignation of Anthony Giovinazzo from the Board of Directors

ProMIS Neurosciences, Inc. to Develop Multivalent Vaccine for Alzheimer’s Disease

First half earnings released